Azafaros, a Leiden, the Netherlands-based clinical-stage company developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, raised €132M in Series B funding.
The round was led by Jeito Capital, co-led by Forbion Growth, with participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV).
Led by CEO Stefano Portolano, Azafaros is a clinical-stage company which specializes in rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of industry experts. It is developing a dual-acting drug candidate to offer new treatment options to patients with lysosomal storage disorders, a group of severe rare genetic diseases that often cause progressive neurodegeneration and, in many cases, fatal outcomes.
The company intends to use the funds to accelerate the development of its lead product, nizubaglustat, scheduled to enter Phase 3 studies for Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses later this year.
FinSMEs
13/05/2025